Menu

Merck Buys Sigma-Aldrich for $17B

Two giants merge as the German drug maker acquires the US-based science supply company.

Sep 22, 2014
Kerry Grens

WIKIMEDIA, GERIBETH CIULLOThe German pharmaceutical and chemical company Merck is purchasing Sigma-Aldrich, which supplies a wide swath of lab reagents, for a whopping $17 billion. According to Reuters, the deal contributes to a record-breaking year for transactions in the healthcare industry, “with year-to-date activity in the sector topping $380 billion, well over double the year-ago level, according to Thomson Reuters data.”

Merck has been growing its lab supply side to become one of the biggest companies in the business, having bought EMD Millipore (a.k.a. Merck Millipore), which sells reagents and lab tools, in 2010. “Sigma helps fill in a lot of the missing pieces” for Merck, Ross Muken, a life sciences industry analyst with ISI Group LLC in New York, told The Wall Street Journal. Merck will now sell the range of life science products, from basic science tools and reagents to pharmaceuticals.

According to the Associated Press, Merck CEO Karl-Ludwig Kley said the firm had a “clear commitment” to St. Louis, Missouri, where Sigma-Aldrich is based. According to the news report, “he said it was too early in the integration process to answer a question about possible job losses at any of the company’s facilities.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.